What's moving this stock lately
1 direct · 0 2nd-order · 0 thematicRanked by relevance and recency.
- #1Impact0.22%bullishDirectThe Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.34d ago
As Moderna's partner and Keytruda co-administration party, Merck's scale dilutes the impact of any single pipeline headline
Also named: MRNA · BNTX · PSNL · ADPT · ILMN · TMO
🎯 Market expectations
Estimate coverage High · 70/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026-$0.13 vs -$0.26+50%
- Mar 2026-$1.28 vs -$1.51+15.23%
- Dec 2025$2.04 vs $2.03+0.49%
- Sep 2025$2.58 vs $2.36+9.32%
The takeaway
Recent results have exceeded consensus by an average of +18.8%, which may have raised expectations for the next report.
Analyst estimates, not our forecast · not investment advice
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $65.0B · latest quarter up 5.1% YoY · profitable (FY net income $18.3B) · short activity within its normal range.
FY revenue
$65.0B
2025-12
Latest Q YoY
+5.1%
FY net income
$18.3B
Diluted EPS
$7.3
Short volume
39.6%
20d avg 36.1% · normal
🐋 5%+ ownership filings (last 180d)
The following investors reported beneficial ownership of more than 5% in recent SEC filings. "Activist" filers stated an intent to influence control of the company; "Passive" indicates the filer did not report such an intent.
- 2026-04-30passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
🕰️ Price × news · analysis history
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
23 past analyses of this stock, each checked against what the price did afterwards · sign up to view
Start my free trialCurrent conviction
Crowding
Risk temperature
Tail risk
Triggers
Money flow
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial